Eosinophil β1 Integrin Activation as a Biomarker for Eosinophilic Esophagitis

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

August 30, 2016

Primary Completion Date

December 13, 2018

Study Completion Date

December 13, 2018

Conditions

Eosinophilic Esophagitis

Interventions

OTHER

Observation Period

8 week observational period

Trial Locations (1)

UW Madison School of Medicine and Public Health, Madison

All Listed Sponsors

collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

University of Wisconsin, Madison

OTHER

NCT02775045 - Eosinophil β1 Integrin Activation as a Biomarker for Eosinophilic Esophagitis | Biotech Hunter | Biotech Hunter